By Gina Shaw
The next two weeks promise to be perhaps the most eventful in the history of the development of vaccines against the virus that causes COVID-19. The first milestone: the FDA released phase 3 trial safety data on Pfizer’s vaccine candidate BNT162b2, developed with Germany’s BioNTech.
“All previous public knowledge about safety and efficacy of this vaccine has been based on the phase 1 to 2 trials and on press releases,” said Litjen (LJ) Tan, MS, PhD,